BofA/Merrill Lynch Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Neutral
Tweet Send to a FriendGet Alerts IDIX Hot Sheet
Price: $5.39 --0%
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Trade IDIX Now!
BofA/Merrill Lynch downgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $5.64 yesterday, with a 52 week range of $4.30-$15.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $5.64 yesterday, with a 52 week range of $4.30-$15.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
- Wells Fargo Cuts Comerica (CMA) and First Horizon National (FHN) to Underperform
- KeyBanc Downgrades Sanderson Farms (SAFM) to Hold
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
Merrill Lynch, Bank of America
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
